Table 2.
Human subjects selected for the lymphocyte proliferation studies
| Normotensive Controls (n = 12) | Hypertensive Patients (n = 10) | |
|---|---|---|
| Age, yr | 49.9 ± 5.9 (41–59) | 50.4 ± 5.8 (41–60) |
| Sex, M/F | 6/6 | 5/5 |
| SBP, mmHg | 118.1 ± 9.74 (110–135) | 154.8 ± 6.72 (149–165) |
| DBP, mmHg | 77.5 ± 6.90 (69–84) | 97.9 ± 2.40 (95–101) |
| FBS, mg/dl | 80.9 ± 11.37 (68–108) | 81.1 ± 7.60 (70–96) |
| Uric acid, mg/dl | 4.9 ± 0.89 (3.6–5.9) | 5.0 ± 0.77 (3.9–5.9) |
| Scr, mg/dl | 0.91 ± 0.12 (0.7–1.1) | 0.98 ± 0.16 (0.7–1.2) |
| TGL, mg/dl | 164.1 ± 34.9 (108–220) | 187.5 ± 35.5 (102–220) |
| CHO, mg/dl | 212.5 ± 18.8 (192–252) | 221.5 ± 15.3 (189–352) |
| Hg, g/dl | 13.0 ± 0.91 (11.9–14.2) | 12.6 ± 1.00 (11.4–14.2) |
| WBC/mm3 | 7007.5 ± 1489.3 (4680–9230) | 6579 ± 1927 (2.350–9520) |
| PMN, % | 70.3 ± 3.3 (65–73) | 69 ± 3.2 (65–75) |
| Lymph, % | 30.5 ± 4.8 (22–39) | 31 ± 3.3 (25–38) |
| Urine sediment | Normal (12/12) | Normal (10/10) |
| UP/C | 10 ± 2 (0–65) | 89 ± 7 (7–205) |
| eGFR | 85.3 ± 23.2 (57–123) | 75.2 ± 8.7 (53–92) |
| Medications | Atorvastatin (2/12) | Nifedipine (5/10), diuretics (10/10), atorvastatin 6/10) |
Values are means ± SD (range). All patients had primary (essential) hypertension. Selection and exclusion criteria listed in the text. SBP, systolic blood pressure; DBP, diastolic blood pressure; FBS, fasting blood sugar; Scr, serum creatinine; TGL, serum triglycerides; CHO, serum cholesterol; Hg, serum hemoglobin; WBC, white blood cell count; PMN. polymorphonuclear leukocytes; Lymph, lymphocytes; UP/C, urinary protein/creatinine ratio; eGFR, estimated glomerular filtration rate by MDRD equation.